PHARMACEUTICAL COMBINATION CONTAINING ALK INHIBITOR AND SHP2 INHIBITOR
FIELD: pharmaceutics.SUBSTANCE: group of inventions relates to a pharmaceutical combination containing ALK inhibitor in a free form or its pharmaceutically acceptable salt and SHP2 inhibitor in a free form or its pharmaceutically acceptable salt, and to its use. A pharmaceutical combination is proposed for the treatment of ALK-positive cancer, including (i) ALK inhibitor or its pharmaceutically acceptable salt, where ALK inhibitor is ceritinib, and (ii) SHP2 inhibitor and, optionally, a pharmaceutically acceptable carrier for simultaneous or subsequent injection. The combination is suitable for the treatment of cancer with rearranged ALK. Joint targeting on ALK and SHP2 amplifies an antiproliferative effect of ALK inhibitor, even in case of cancer resistant to ALK inhibitor.EFFECT: inventions provide the reduction in RAS-GTP loading cell potential and inhibit the restoration of phospho-ERK, which can overcome non-targeted resistance in cancer with rearranged ALK, such as NSCLC.15 cl, 4 dwg, 3 tbl, 5 ex.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 28. März Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HAO HUAIXIANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-03-28, Last update posted on www.tib.eu: 2024-04-24, Last updated: 2024-05-03 |
|---|
| Patentnummer: |
RU2769132 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002026740 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002026740 | ||
| 003 | DE-627 | ||
| 005 | 20240503111406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002026740 | ||
| 035 | |a (EPA)RU2769132 | ||
| 035 | |a (EPA)61028108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HAO HUAIXIANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMBINATION CONTAINING ALK INHIBITOR AND SHP2 INHIBITOR |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-03-28, Last update posted on www.tib.eu: 2024-04-24, Last updated: 2024-05-03 | ||
| 520 | |a FIELD: pharmaceutics.SUBSTANCE: group of inventions relates to a pharmaceutical combination containing ALK inhibitor in a free form or its pharmaceutically acceptable salt and SHP2 inhibitor in a free form or its pharmaceutically acceptable salt, and to its use. A pharmaceutical combination is proposed for the treatment of ALK-positive cancer, including (i) ALK inhibitor or its pharmaceutically acceptable salt, where ALK inhibitor is ceritinib, and (ii) SHP2 inhibitor and, optionally, a pharmaceutically acceptable carrier for simultaneous or subsequent injection. The combination is suitable for the treatment of cancer with rearranged ALK. Joint targeting on ALK and SHP2 amplifies an antiproliferative effect of ALK inhibitor, even in case of cancer resistant to ALK inhibitor.EFFECT: inventions provide the reduction in RAS-GTP loading cell potential and inhibit the restoration of phospho-ERK, which can overcome non-targeted resistance in cancer with rearranged ALK, such as NSCLC.15 cl, 4 dwg, 3 tbl, 5 ex | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI FANG |e verfasserin |4 aut | |
| 700 | 0 | |a LAMARCHE MATTHEW J |e verfasserin |4 aut | |
| 700 | 0 | |a WANG HUI-QIN |e verfasserin |4 aut | |
| 700 | 0 | |a DARDAEI ALGHALANDIS LEILA |e verfasserin |4 aut | |
| 700 | 0 | |a ENGELMAN JEFFREY ADAM |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 28. März |
| 773 | 1 | 8 | |g year:2022 |g day:28 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/61028108/publication/RU2769132A1?q=RU2769132 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 28 |c 03 | ||